Musculoskeletal radiology tests - DXA

Role

DXA (dual-energy X-ray absorptiometry) measures bone mineral density - in rheumatology, used both for standard osteoporosis screening and specifically to monitor bone loss associated with inflammatory rheumatic disease and its treatment (particularly long-term corticosteroid use)
Rheumatic disease patients carry elevated osteoporosis/fracture risk from multiple compounding factors - chronic inflammation itself (cytokine-driven bone resorption), reduced mobility, and glucocorticoid treatment - making DXA a routinely relevant test in this population beyond standard age-based screening

Chronic inflammatory cytokines (TNF-alpha, IL-6, IL-1) directly stimulate osteoclast activity via the RANK/RANKL pathway, causing bone loss independent of corticosteroid use - explaining why active, poorly controlled inflammatory disease itself (not just its treatment) is an independent osteoporosis risk factor

T-score interpretation follows the same WHO criteria as general osteoporosis screening (see DXA bone scan reports for detail) - normal >=-1.0, osteopenia -1.0 to -2.5, osteoporosis <=-2.5
Glucocorticoid-induced osteoporosis has a lower fracture risk threshold than typical postmenopausal osteoporosis at an equivalent T-score, given glucocorticoids' additional direct suppression of osteoblast function (not just increased resorption) - fracture risk assessment tools in this context should specifically account for glucocorticoid exposure, not treat it as equivalent to standard age-related bone loss

Patients starting or continuing prolonged glucocorticoid therapy (generally >=3 months at a moderate-high dose) should have baseline DXA and be considered for prophylactic bone-protective therapy (bisphosphonates typically first-line) proactively, rather than waiting for a fracture or a follow-up DXA to show established osteoporosis
Optimising control of the underlying inflammatory disease itself (reducing cytokine-driven bone loss) is a complementary bone-protective strategy alongside specific anti-osteoporosis therapy

Glucocorticoid-induced osteoporosis, rheumatoid arthritis-associated bone loss, fragility fracture risk in chronic inflammatory disease

Glucocorticoid-induced bone loss occurs disproportionately early after starting treatment (with the most rapid loss in the first 3-6 months) - proactive bone protection at treatment initiation, not reactive treatment after a low DXA result, is the recommended approach for patients starting significant, prolonged glucocorticoid therapy

5 more sections, plus exam facts

Premium unlocks every note across every specialty, and the full exam fact library behind it.